Skip to content
Sign In

Main Navigation

James Sharp Logo
  • Individuals
    Individuals

    Choose Your Level of Service

    • Discretionary ServiceDiscretionary Service
    • Execution Only ServiceExecution Only Service
  • Charities & Trustees
    Charities & Trustees

    Choose Your Level of Service

    • Discretionary ServiceDiscretionary Service
    • Execution Only ServiceExecution Only Service

  • Companies
    Companies

    Choose Your Level of Service

    • Discretionary ServiceDiscretionary Service
    • Execution Only ServiceExecution Only Service

  • News & Insights
    • News & Insights
    • Current Research Coverage List
  • About Us
    • About Us
    • Our People
  • Conectus Portal
  • Contact Us

Update - Page 66

9 December 2024

GSK plc Blenrep Combination China Filing Acceptance

Blenrep (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma GSK plc (LSE/NYSE: GSK) today announced that the National Medical Products…

9 December 2024

GSK plc Nucala COPD Submission Accepted by FDA

US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA)…

6 December 2024

AVI Global Trust plc Annual Overview

AVI Global Trust – Annual overview from QuotedData 6th December 2024 Building on solid foundations AVI Global (AGT) continues to demonstrate the value of a clear strategy…

5 December 2024

Hargreaves Services plc Trading Update and Notice of Interim Results

Hargreaves Services plc (“Hargreaves”, the “Company” or the “Group”) Trading Update and Notice of Interim Results Hargreaves Services plc (AIM: HSP), a diversified group delivering services…

5 December 2024

Sequoia Half-Year Report

Sequoia Economic Infrastructure Income Fund Limited (the “Company”) STRONG INTEREST INCOME GENERATION FROM RESILIENT PORTFOLIO WELL POSITIONED TO DELIVER ATTRACTIVE AND SUSTAINABLE RETURNS Interim…

5 December 2024

GSK plc Update Zhifei Collaboration

GSK and Zhifei revise and extend strategic vaccine collaboration in China GSK plc (LSE/NYSE: GSK) today announced that it has entered into an agreement…

5 December 2024

AstraZeneca’s Imfinzi Approved In US For Limited-Stage SCLC

Imfinzi approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer  Based on ADRIATIC Phase III trial…

4 December 2024

Finsbury Growth & Income Trust plc Final Results

Finsbury Growth & Income Trust PLC (the “Company”) This announcement contains regulated information Annual Financial Report for the year ended 30 September 2024 Finsbury…

Posts navigation

  • «
  • 1
  • …
  • 64
  • 65
  • 66
  • 67
  • 68
  • …
  • 86
  • »

Home > Update > Page 66

James Sharp white Logo
Sign In
Linkedin Icon

The Exchange
5 Bank Street
Bury, Lancashire
BL9 0DN

Tel: 0161 764 4043

Fax: 0161 764 1628

Email: mail@jamessharp.co.uk

Linkedin Icon

James Sharp & Co is a trading name
of James Sharp & Co LLP (0C422665)

Members of the LLP are referred to as Partners

  • Downloads & Resources
  • Complaints
  • Financial Compensation Scheme
  • Conectus Portal

  • Cyber Essentials Certification
  • Website Terms & Conditions
  • Privacy Policy
  • Cookie policy
  • Consent Preferences

Email Newsletter Sign-up

Consent(Required)
What we do with you information. Find out more

© Copyright 2010-2026. All rights reserved. James Sharp & Co. Authorised & Regulated by the Financial Conduct Authority
Member of the London Stock Exchange - Member of the Aquis Stock Exchange - Member of PIMFA

Website by ICG